Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about ProKidney Corp.
ProKidney Corp. News
ProKidney Corp. Quantitative Score
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
ProKidney Corp. Financials
Table Compare
Compare PROK metrics with: | |||
|---|---|---|---|
Earnings & Growth | PROK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PROK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PROK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PROK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
ProKidney Corp. Income
ProKidney Corp. Balance Sheet
ProKidney Corp. Cash Flow
ProKidney Corp. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Neutral |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
ProKidney Corp. Executives
| Name | Role |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer & Director |
| Mr. Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Secretary |
| Dr. Ulrich Ernst Ph.D. | EVice President of Science and Technology |
| Mr. James Coulston CPA | Chief Financial Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer & Director | 1969 | 1.02M | |
| Mr. Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Secretary | Male | 1965 | 635.86K |
| Dr. Ulrich Ernst Ph.D. | EVice President of Science and Technology | 1963 | 622.74K | |
| Mr. James Coulston CPA | Chief Financial Officer | Male | 1977 | 533.15K |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs | -- |
ProKidney Corp. Insider Trades
| Date | 3 Jun |
| Name | Legorreta Pablo G. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | C-Conversion |
| Shares | 3823996 |
| Date | 3 Jun |
| Name | Legorreta Pablo G. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 3823996 |
| Date | 3 Jun |
| Name | Legorreta Pablo G. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | C-Conversion |
| Shares | 3823996 |
| Date | 3 Jun |
| Name | Legorreta Pablo G. |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | C-Conversion |
| Shares | 3823996 |
| Date | 29 May |
| Name | Legorreta Pablo G. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 125862 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Jun | Legorreta Pablo G. | Director, 10 percent owner | Acquired | C-Conversion | 3823996 |
| 3 Jun | Legorreta Pablo G. | Director, 10 percent owner | Disposed | J-Other | 3823996 |
| 3 Jun | Legorreta Pablo G. | Director, 10 percent owner | Disposed | C-Conversion | 3823996 |
| 3 Jun | Legorreta Pablo G. | Director, 10 percent owner | Disposed | C-Conversion | 3823996 |
| 29 May | Legorreta Pablo G. | Director, 10 percent owner | Acquired | A-Award | 125862 |